糖尿病肾病的管理：最新进展
Management of diabetic kidney disease: Recent advances.
作者信息
Agarwal Pankaj
机构信息
Hormone Care and Research Centre, Ghaziabad, Uttar Pradesh, India.
出版信息
Indian J Endocrinol Metab. 2013 Oct;17(Suppl 1):S55-8. doi: 10.4103/2230-8210.119506.
Abstract
Diabetic kidney disease, in present days, is being recognized as the commonest cause of end stage renal disease. Though there is no absolute therapy for diabetic kidney disease, decades of hard work has recognized some modifiable factors that can prevent its progression. This article is an attempt to review some recent advances in the understanding, diagnosis and management of diabetic kidney disease.
摘要
如今，糖尿病肾病被认为是终末期肾病最常见的病因。尽管糖尿病肾病尚无绝对的治疗方法，但数十年来的努力已识别出一些可改变的因素，这些因素能够预防其进展。本文旨在综述糖尿病肾病在认识、诊断和管理方面的一些最新进展。
相似文献
1
Management of diabetic kidney disease: Recent advances.糖尿病肾病的管理：最新进展
Indian J Endocrinol Metab. 2013 Oct;17(Suppl 1):S55-8. doi: 10.4103/2230-8210.119506.
2
Diabetic kidney disease: New clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function".糖尿病肾病：新的临床和治疗问题。意大利糖尿病学会和意大利肾脏病学会关于“糖尿病肾病的自然病程和肾功能受损的 2 型糖尿病患者的高血糖治疗”的联合立场声明。
Nutr Metab Cardiovasc Dis. 2019 Nov;29(11):1127-1150. doi: 10.1016/j.numecd.2019.07.017. Epub 2019 Oct 2.
3
Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function".糖尿病肾病：新的临床和治疗问题。意大利糖尿病学会和意大利肾脏病学会关于“糖尿病肾病的自然病程和肾功能受损的 2 型糖尿病患者的高血糖治疗”的联合立场声明。
J Nephrol. 2020 Feb;33(1):9-35. doi: 10.1007/s40620-019-00650-x.
4
New insights into molecular mechanisms of diabetic kidney disease.糖尿病肾病分子机制的新见解。
Am J Kidney Dis. 2014 Feb;63(2 Suppl 2):S63-83. doi: 10.1053/j.ajkd.2013.10.047.
6
More than just an enzyme: Dipeptidyl peptidase-4 (DPP-4) and its association with diabetic kidney remodelling.不仅仅是一种酶：二肽基肽酶-4（DPP-4）及其与糖尿病肾病重塑的关联。
Pharmacol Res. 2019 Sep;147:104391. doi: 10.1016/j.phrs.2019.104391. Epub 2019 Aug 8.
7
Metabolic Surgery to Treat Obesity in Diabetic Kidney Disease, Chronic Kidney Disease, and End-Stage Kidney Disease; What Are the Unanswered Questions?代谢手术治疗糖尿病肾病、慢性肾脏病和终末期肾病的肥胖症：有哪些未解答的问题？
Front Endocrinol (Lausanne). 2020 Aug 17;11:289. doi: 10.3389/fendo.2020.00289. eCollection 2020.
8
Recent advances in managing and understanding diabetic nephropathy.糖尿病肾病管理与认识的最新进展
F1000Res. 2016 May 31;5. doi: 10.12688/f1000research.7693.1. eCollection 2016.
9
The future of diabetic kidney disease management: what to expect from the experimental studies?糖尿病肾病管理的未来：实验研究中有哪些值得期待？
J Nephrol. 2020 Dec;33(6):1151-1161. doi: 10.1007/s40620-020-00724-1. Epub 2020 Mar 27.
10
Diabetic Nephropathy: New Risk Factors and Improvements in Diagnosis.糖尿病肾病：新的危险因素与诊断进展
Rev Diabet Stud. 2015 Spring-Summer;12(1-2):110-8. doi: 10.1900/RDS.2015.12.110. Epub 2015 Aug 10.
引用本文的文献
1
Effect of echinacoside on kidney fibrosis by inhibition of TGF-β1/Smads signaling pathway in the db/db mice model of diabetic nephropathy.紫锥菊苷通过抑制糖尿病肾病db/db小鼠模型中的TGF-β1/Smads信号通路对肾纤维化的影响
Drug Des Devel Ther. 2017 Sep 21;11:2813-2826. doi: 10.2147/DDDT.S143805. eCollection 2017.
2
The use of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes & chronic kidney disease.二肽基肽酶-4抑制剂在2型糖尿病合并慢性肾脏病患者中的应用
Nurse Pract. 2017 Jun 16;42(6):31-38. doi: 10.1097/01.NPR.0000512253.40369.ab.
3
Cordyceps militaris Treatment Preserves Renal Function in Type 2 Diabetic Nephropathy Mice.蛹虫草治疗可保护2型糖尿病肾病小鼠的肾功能。
PLoS One. 2016 Nov 10;11(11):e0166342. doi: 10.1371/journal.pone.0166342. eCollection 2016.
4
Human resources, patient load, and infrastructure at institutions providing diabetic care in India: The India 11-city 9-state study.印度提供糖尿病护理机构的人力资源、患者数量及基础设施：印度11个城市9个邦的研究。
Indian J Endocrinol Metab. 2016 Apr;20(Suppl 1):S11-8. doi: 10.4103/2230-8210.179769.
5
Management of anemia in patients with diabetic kidney disease: A consensus statement.糖尿病肾病患者贫血的管理：一项共识声明。
Indian J Endocrinol Metab. 2016 Mar-Apr;20(2):268-81. doi: 10.4103/2230-8210.176348.
本文引用的文献
1
[Special issue: Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2012].[特刊：《2012年慢性肾脏病诊断与治疗临床实践指南》]
Nihon Jinzo Gakkai Shi. 2012;54(8):1034-191.
2
KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update.KDIGO 临床实践指南：糖尿病与慢性肾脏病（2012 年更新版）
Am J Kidney Dis. 2012 Nov;60(5):850-86. doi: 10.1053/j.ajkd.2012.07.005.
3
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.辛伐他汀联合依折麦布降低慢性肾脏病患者 LDL 胆固醇的效果（心脏和肾脏保护研究）：一项随机安慰剂对照试验。
Lancet. 2011 Jun 25;377(9784):2181-92. doi: 10.1016/S0140-6736(11)60739-3. Epub 2011 Jun 12.
4
Rosuvastatin in diabetic hemodialysis patients.瑞舒伐他汀在糖尿病血液透析患者中的应用。
J Am Soc Nephrol. 2011 Jul;22(7):1335-41. doi: 10.1681/ASN.2010090987. Epub 2011 May 12.
5
Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort.1型糖尿病合并微量白蛋白尿患者的长期肾脏转归：糖尿病控制与并发症试验/糖尿病干预与并发症流行病学队列分析
Arch Intern Med. 2011 Mar 14;171(5):412-20. doi: 10.1001/archinternmed.2011.16.
6
Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: clinical recommendations.新型检测方法用于检测 2 型糖尿病合并不同肾功能水平患者的二甲双胍水平：临床建议。
Diabetes Care. 2010 Jun;33(6):1291-3. doi: 10.2337/dc09-1284. Epub 2010 Mar 9.
7
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.2型糖尿病患者使用二甲双胍发生致命性和非致命性乳酸性酸中毒的风险。
Cochrane Database Syst Rev. 2010 Jan 20(1):CD002967. doi: 10.1002/14651858.CD002967.pub3.
8
Recent advances in pharmacotherapy for diabetic nephropathy: current perspectives and future directions.糖尿病肾病药物治疗的最新进展：当前观点与未来方向
Pharmacol Res. 2009 Jul;60(1):24-32. doi: 10.1016/j.phrs.2009.02.002. Epub 2009 Feb 14.
9
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.替米沙坦、雷米普利或二者联用对高血管风险人群的肾脏结局影响（ONTARGET研究）：一项多中心、随机、双盲、对照试验
Lancet. 2008 Aug 16;372(9638):547-53. doi: 10.1016/S0140-6736(08)61236-2.
10
A novel class of advanced glycation inhibitors ameliorates renal and cardiovascular damage in experimental rat models.一类新型的晚期糖基化抑制剂可改善实验大鼠模型中的肾脏和心血管损伤。
Nephrol Dial Transplant. 2008 Feb;23(2):497-509. doi: 10.1093/ndt/gfm601. Epub 2007 Oct 10.
Zotero 插件